Kenneth Cawkell, LLB – Director & CEO
Mr. Cawkell has over 25 years of experience as both a biotech entrepreneur & general counsel, during this time he has gained extensive strategic and development insight into all aspects of drug development, financing, licensing and M&A transactions. He was primarily responsible developing the Company’s de-risked, drug development strategy that led to the identification and acquisition of the Memogain Technology, his long term association with numerous public and private biotechnology companies has led to several successful exits.
Denis G. Kay, Ph.D – CSO
Dr. Kay has 25 years of neuroscience experience, science entrepreneur, co-inventor & developer of Parkinson’s models, extensive university, hospital and industry experience in CNS therapeutic development.
Fred Sancilio, Ph.D – Senior Executive
Dr. Sancilio, a founder director of several pharma companies & CROs, has over 30 years of experience in all aspects of drug development from research to executing clinical and regulatory strategies, financing and pharma licensing exits.
Philippe Calais – Senior Consultant
Dr. Calais has been a biotech entrepreneur for over 30 years gaining global corporate and development expertise combined with broad therapeutic experience including CNS and AD in all aspects of the drug development from discovery through partnership & commercialization.